Accendra Health grants shares to EVP counsel

Galloway Heath H reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Galloway Heath H reported acquisition or exercise transactions in this Form 4 filing.

ACCENDRA HEALTH INC/VA/ granted EVP, General Counsel & Corporate Secretary Heath H. Galloway 61,437 shares of Common Stock as a restricted stock award. The grant carries no purchase price and vests one-third per year over three years. Following this compensation award, Galloway directly holds 178,441 Common Stock shares. This is a non-market, equity-based compensation grant rather than an open-market purchase or sale, so it reflects long-term incentive alignment more than a trading view on the stock.

Insider Trade Summary

Grant/Award: 61,437 shares

Grant/Award 1 txn

Insider Galloway Heath H

Role EVP,General Counsel & CorpSecy

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	61,437	$0.00	$0.00

Holdings After Transaction: Common Stock — 178,441 shares (Direct)

Footnotes (1)

1. F1. Restricted stock grant which vests one-third per year over three years.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ACCENDRA HEALTH (ACH) insider Heath H. Galloway report on this Form 4?

Heath H. Galloway reported receiving a grant of 61,437 shares of ACCENDRA HEALTH Common Stock as restricted stock. The award is compensation, not an open-market trade, and increases his direct equity stake in the company.

What type of transaction is shown in the ACCENDRA HEALTH (ACH) Form 4 for Heath H. Galloway?

The Form 4 shows a grant or award acquisition of Common Stock, coded as “A”. This represents equity compensation granted by the company, not shares bought or sold in the market, and therefore carries limited trading-signal value for investors.

How many ACCENDRA HEALTH (ACH) shares did Heath H. Galloway receive and at what price?

Heath H. Galloway received 61,437 shares of ACCENDRA HEALTH Common Stock at a stated price per share of $0.0000. This indicates the award was granted as compensation rather than purchased for cash in an open-market or private transaction.

What is the vesting schedule for Heath H. Galloway’s ACCENDRA HEALTH restricted stock grant?

The restricted stock grant vests one-third per year over three years. This staggered vesting schedule encourages ongoing service and long-term alignment, as full ownership of all 61,437 shares will only occur after three annual vesting dates.

How many ACCENDRA HEALTH (ACH) shares does Heath H. Galloway hold after this Form 4 transaction?

After the reported grant, Heath H. Galloway directly holds 178,441 shares of ACCENDRA HEALTH Common Stock. This figure includes the newly awarded restricted shares and reflects his total direct beneficial ownership position following the transaction.

Is the ACCENDRA HEALTH (ACH) Form 4 transaction a market buy or sell of shares?

No, the Form 4 transaction is not a market buy or sell. It is a restricted stock grant reported with transaction code “A,” meaning a grant, award, or other acquisition provided as compensation rather than a trade executed on a stock exchange.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/10/2026 - 09:01 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Galloway Heath H

(Last) (First) (Middle)

ACCENDRA HEALTH INC.

4435 WATERFRONT DRIVE

(Street)

GLEN ALLEN VA 23060

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ACCENDRA HEALTH INC/VA/ [ ACH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP,General Counsel & CorpSecy

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	03/09/2026		A		61,437	A	$0	178,441	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock grant which vests one-third per year over three years.

	Heath H. Galloway by Rosemarie France, POA	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.